Recent developments in cyclooxygenase inhibition.

[1]  L F Watson,et al.  Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.

[2]  L. Marnett,et al.  Control of Prostaglandin Stereochemistry at the 15-Carbon by Cyclooxygenases-1 and -2 , 2002, The Journal of Biological Chemistry.

[3]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[4]  M. Percival,et al.  A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Marnett,et al.  Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol* , 2001, The Journal of Biological Chemistry.

[6]  R. Kurumbail,et al.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. , 2001, The Biochemical journal.

[7]  P. Loll,et al.  Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. , 2001, Biochemistry.

[8]  A. Kalgutkar,et al.  Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. , 2001, Current drug targets.

[9]  R Gordon,et al.  Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[11]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[12]  L. Marnett,et al.  Tyrosine-385 Is Critical for Acetylation of Cyclooxygenase-2 by Aspirin , 2000 .

[13]  L. Marnett,et al.  Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. , 2000, Biochemistry.

[14]  C. Koboldt,et al.  N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.

[15]  R. S. Rogers,et al.  4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. , 2000, Journal of medicinal chemistry.

[16]  L. Marnett,et al.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Bayly,et al.  Structure-based design of COX-2 selectivity into flurbiprofen. , 1999, Bioorganic & medicinal chemistry letters.

[18]  L. Marnett,et al.  Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. , 1998, Journal of medicinal chemistry.

[19]  L. Marnett,et al.  Aspirin-like molecules that covalently inactivate cyclooxygenase-2. , 1998, Science.

[20]  C. Cywin,et al.  Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2. , 1998, Bioorganic & medicinal chemistry letters.

[21]  R. Darolia,et al.  New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent. , 1998, Journal of medicinal chemistry.

[22]  L. Marnett,et al.  Investigation of the binding of isoform-selective inhibitors to prostaglandin endoperoxide synthases using fluorescence spectroscopy. , 1998, Biochemistry.

[23]  C. Bayly,et al.  The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. , 1997, Molecular pharmacology.

[24]  C. Bayly,et al.  Conversion of Prostaglandin G/H Synthase-1 into an Enzyme Sensitive to PGHS-2-selective Inhibitors by a Double His513 → Arg and Ile523 → Val Mutation* , 1997, The Journal of Biological Chemistry.

[25]  J. Chow,et al.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.

[26]  J. Falgueyret,et al.  Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2. , 1996, Biochemistry.

[27]  Ke-He Ruan,et al.  Role of Val509 in Time-dependent Inhibition of Human Prostaglandin H Synthase-2 Cyclooxygenase Activity by Isoform-selective Agents* , 1996, The Journal of Biological Chemistry.

[28]  J. Gierse,et al.  A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors* , 1996, The Journal of Biological Chemistry.

[29]  C. Bayly,et al.  From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors , 1996 .

[30]  William L. Smith,et al.  Involvement of Arginine 120, Glutamate 524, and Tyrosine 355 in the Binding of Arachidonate and 2-Phenylpropionic Acid Inhibitors to the Cyclooxygenase Active Site of Ovine Prostaglandin Endoperoxide H Synthase-1 (*) , 1996, The Journal of Biological Chemistry.

[31]  Daniel Picot,et al.  The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.

[32]  C. Wei,et al.  Comparison of branched-chain and tightly coupled reaction mechanisms for prostaglandin H synthase. , 1995, Biochemistry.

[33]  S Jothy,et al.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.

[34]  R. Copeland,et al.  Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[36]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[37]  L. Marnett,et al.  Acetylation of prostaglandin endoperoxide synthase by N-acetylimidazole: comparison to acetylation by aspirin. , 1992, Biochemistry.

[38]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[39]  Eveline,et al.  The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. , 1990, The Journal of biological chemistry.

[40]  L. Rome,et al.  Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Majerus,et al.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. , 1975, The Journal of clinical investigation.

[42]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[43]  L. Marnett,et al.  COX-2: a target for colon cancer prevention. , 2002, Annual review of pharmacology and toxicology.

[44]  J. Talley,et al.  Selective inhibitors of cyclooxygenase-2 (COX-2). , 1999, Progress in medicinal chemistry.

[45]  D. Riendeau,et al.  Chapter 21. Selective Cyclooxygenase-2 Inhibitors , 1997 .

[46]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[47]  P. Majerus,et al.  Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that forms prostaglandins. , 1976, Prostaglandins.